Pacira BioSciences, Inc. features 78% margins and NOPAIN Act tailwinds; its 5.5x EV/EBITDA multiple reflects patent fears.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results